PDL BioPharma, Inc. Debt/Equity

Debt/Equity of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 29, 2020 was 0.03 (a 34.17% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -84.5%
  • Annual Debt/Equity for 2019 was 0.05 (a -73.13% decrease from previous year)
  • Annual Debt/Equity for 2018 was 0.17 (a 23.05% increase from previous year)
  • Annual Debt/Equity for 2017 was 0.14 (a -54.89% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of PDL BioPharma, Inc.

Most recent Debt/Equityof PDLI including historical data for past 10 years.

Interactive Chart of Debt/Equity of PDL BioPharma, Inc.

PDL BioPharma, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.03 0.02
2019 0.05 0.21 0.19 0.18 0.05
2018 0.17 0.17 0.17 0.14 0.17
2017 0.14 0.14 0.14 0.15 0.14
2016 0.31 0.31 0.32 0.31 0.31
2015 0.33 0.47 0.53 0.62 0.33
2014 0.6 0.68 0.92 1.34 0.6
2013 0.0 2.78 -115.62 -3.34 0.0
2012 -4.55 -2.66 -1.89 -1.24 -4.55
2011 -1.55 -1.3 -1.13 -0.66 -1.55
2010 -1.22 -1.12 -0.89 -1.22

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.